- Details
- Stephen Williams discusses the evolving role of blue light cystoscopy in detecting non-muscle invasive bladder cancer (NMIBC). The conversation covers its pathophysiology, diagnostic and surveillance applications, emphasizing selective utilization and benefits post-BCG therapy. Dr. Williams references a study in Clinical Genitourinary Cancer, sharing insights from a study comparing blue and white...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trials in bladder cancer. They focus on low and intermediate-risk non-muscle invasive bladder cancer, emphasizing the need for well-designed trials to advance treatment. The panel, comprising 25 multidisciplinary experts, aims to guide late-phase...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trial design in high-risk non-muscle-invasive bladder cancer. The consensus statement, led by Dr. Ashish Kamat and published in the Journal of Clinical Oncology, aims to guide investigators in late-phase clinical trial design. The panel, comprisi...
|
- Details
- Kriti Mittal and Guru Sonpavde discuss advancements in the treatment of non-muscle invasive bladder cancer. Dr. Mittal highlights the FDA's 2020 approval of pembrolizumab for high-risk, BCG-unresponsive cases, based on the KEYNOTE-057 study. This study demonstrated a notable clinical response at three and twelve months. Atezolizumab, although showing some response, didn't meet its threshold in a s...
|
- Details
- Ashish Kamat and Morgan Rouprêt explore advancements in non-muscle-invasive bladder cancer (NMIBC) treatments. Professor Rouprêt emphasizes two NMIBC categories: high-grade disease, where muscle-invasive and high-grade bladder cancer lines blur, and low-grade disease, where de-intensification of follow-up and treatment is sought. He highlights the THOR-2 cohort presented by Jim Catto at ESMO, show...
|
- Details
- Zach Klaassen and Gautam (Tom) Jayram explore the use of blue light cystoscopy in bladder cancer. Dr. Jayram explains its mechanism, where an optical agent, interacting with the heme biosynthetic pathway, causes cancer cells to accumulate photo porphyrins that light up under specific wavelengths. This technology is crucial for patients suspected of having or with a history of bladder cancer, enhan...
|
- Details
- Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic virus targeting cells with retinoblastoma pathway defects, common in cancer cells. This treatment, when instilled in the bladder, prompts immune cells to destroy cancer cells. Highlighted are several key trials: CORE-00...
|
- Details
- Siamak Daneshmand hosts Trinity Bivalacqua to discuss advancements in non-muscle invasive bladder cancer, particularly focusing on newly FDA-approved therapies. Dr. Bivalacqua highlights the excitement surrounding the approval of new treatments for BCG unresponsive bladder cancer, including pembrolizumab and nadofaragene (ADSTILADRIN). He explains the significance of these developments, particular...
|
- Details
- Zach Klaassen hosts Mark Tyson for a discussion on the noninvasive urinary genomic biomarker test, Cxbladder. Dr. Tyson explains that Cxbladder Detect assesses bladder cancer risk in patients with microscopic hematuria by analyzing urine for specific mRNA biomarkers. The test aims to reduce invasive diagnostics like cystoscopy, aligning with AUA guidelines for a risk-stratified approach. Their dec...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the ATLAS publication focusing on the treatment of low-grade intermediate-risk, non-muscle-invasive bladder cancer using UGN-102, with or without TURBT, in a phase III trial. The trial's main objective was to evaluate the efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, versus traditional TURBT alone. Conducted across 72 sites in t...
|
